Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)

Federal funding opportunity RFA-AI-24-080 from National Institutes of Health (Department of Health and Human Services).

Program funding history

Synopsis

Who can apply

• Public housing authorities/Indian housing authorities
• County governments
• Public and State controlled institutions of higher education
• Private institutions of higher education
• Native American tribal organizations (other than Federally recognized tribal governments)
• For profit organizations other than small businesses
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• State governments
• Special district governments
• City or township governments
• Small businesses
• Independent school districts
• Native American tribal governments (Federally recognized)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

The official record

Similar grants

• CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
  PAR-25-077 · National Institutes of Health · closes October 16, 2026
• Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
  RFA-AI-28-024 · National Institutes of Health · closes February 11, 2027
• Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
  RFA-HL-26-017 · National Institutes of Health · closes December 23, 2027
• Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
  RFA-HL-26-018 · National Institutes of Health · closes December 23, 2027
• Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)
  RFA-AI-27-014 · National Institutes of Health · closes October 9, 2028
• Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
  RFA-AI-27-002 · National Institutes of Health · closes November 10, 2026